HaemaLogiX is a clinical stage Australian biotechnology company, advancing a pipeline of next generation immunotherapies for blood cancers and B-cell disorders. Unlike current therapies, HaemaLogiX’s products preserve the patient’s immune system, helping to fight the cancer and maintain resistance to life-threatening infections during treatment.
HaemaLogiX is committed to advancing highly effective immunotherapies for multiple myeloma - a currently incurable disease - in a large and growing global market, valued at approximately US$25.8 billion in 2025, growing to US$37.0 billion by 2030, at approximately 8.4% CAGR.
Multiple myeloma is the world’s second most common blood cancer, with approximately 188,000 new cases diagnosed globally each year.2 Current therapies fall short with greater than 60% of patients failing standard-of-care and progressing to subsequent lines of therapy with poorer outcomes and increased safety risks.3 The result is that ~42% of patients will not live more than five years past diagnosis.4 This underscores the great unmet medical need for safer and more efficacious treatment options.5
HaemaLogiX is sharply focused on developing highly effective drugs for the large (US$23b) and growing (>6% p.a.) multiple myeloma market, a disease with no cure1
HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) expressed on the surface of blood cancer cells, as identified by the company. HaemaLogiX’s two novel antigens are:
Approximately 70% of myeloma patients are kappa-type and would express KMA and 30% are lambda-type and would express LMA on their myeloma plasma cells. Myeloma patients only express one or the other antigen on their myeloma plasma cells.
Over the past decade, HaemaLogiX has built an immunotherapy pipeline that is supported by a strong management team, an experienced Board and internationally recognised Scientific Advisory Board. It has also established strategic clinical research partnerships with leading global cancer institutes, hospitals and cell therapy companies to progress the clinical development of these immunotherapies in multiple myeloma and related diseases.
Triangle Insights
Mafra A, Laversanne M, Marcos-Gragera R et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 2025 May 1;117(5):907-914.
Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020 Nov 10;20(1):1087
Triangle Insights
'A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma,' BJ Haem
HaemaLogiX develops targeted antibody and CAR-T cell therapies for multiple myeloma and related B-cell cancers, focused on the Kappa and Lambda Myeloma Antigens — cell-surface targets no other company is pursuing.
HaemaLogiX was founded in 2014 and incorporated in Victoria, Australia, on 11 December 2014. It converted from a proprietary company to a public company limited by shares on 14 December 2021.
HaemaLogiX's registered office is in Sydney. It operates across Sydney and Melbourne, reflecting close ties with clinical and research partners including the Peter MacCallum Cancer Centre, Alfred Health and the Westmead Institute of Medical Research.
HaemaLogiX is the only company developing therapies against KMA and LMA. These antigens appear on malignant plasma cells but are absent from healthy plasma cells. HaemaLogiX's clinical programs are designed to test whether this selectivity allows myeloma cells to be targeted while sparing normal immune function — the premise its trials are evaluating.